SCHEMBL4776134

SCHEMBL4776134

NC(=O)C=Cc1ccc(Cc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 2/20 0.55
PLA2G10 O15496 1/20 0.55
PLA2G2A P14555 1/20 0.55
HDAC8 Q9BY41 3/20 0.51
HDAC3 O15379 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51
ESR1 P03372 1/20 0.50
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
AKR1B10 O60218 2/20 0.47
AKR1B1 P15121 2/20 0.47
CA12 O43570 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451894 0.93 HDAC8 (0.56) TBXAS1PLA2G10PLA2G2AHDAC8HDAC3
SCHEMBL28087116 0.89 AKR1B10 (0.53) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL2772402 0.85 TBXAS1 (0.71) TBXAS1HDAC8HDAC3HDAC1HDAC2
SCHEMBL459101 0.85 TBXAS1 (0.71) TBXAS1HDAC8HDAC3HDAC1HDAC2
SCHEMBL28087042 0.83 MAPT (0.61) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL27680047 0.83 MAPT (0.61) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL20303734 0.82 MAPT (0.67) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL3239009 0.82 MAPT (0.67) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL20303732 0.82 MAPT (0.67) HDAC8HDAC3HDAC1HDAC2ESR1
SCHEMBL649508 0.82 MAPT (0.67) HDAC8HDAC3HDAC1HDAC2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108963389-B Gelable system for lithium-air battery and preparation method and application thereof 北京师范大学 2020-11-13 CN claimed
EP-1885352-A2 COMBINATIONS COMPRISING JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS Novartis AG (US) 2008-02-13 EP claimed
WO-2006056399-A2 COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS NOVARTIS AG (CH) 2006-06-01 WO claimed
CN-110066281-B Multi-target anti-tumor activity evodiamine derivative, and preparation method and application thereof 中国人民解放军第二军医大学 2024-01-30 CN disclosed
CN-108962627-B Organic system super capacitor or capacitance battery 北京师范大学 2021-01-26 CN disclosed
CN-108963389-B Gelable system for lithium-air battery and preparation method and application thereof 北京师范大学 2020-11-13 CN disclosed
CN-110172056-A New aminopyridine derivative 诺华股份有限公司 2019-08-27 CN disclosed
CN-105452235-B Substituted quinazoline-4-one derivatives 诺华股份有限公司 2019-08-09 CN disclosed
CN-110066281-A Rutaecarpin derivative of multiple target point anti-tumor activity and the preparation method and application thereof 中国人民解放军第二军医大学 2019-07-30 CN disclosed
CN-110003192-A Substituted amino-metadiazine compound and its application method and purposes 广东东阳光药业有限公司 2019-07-12 CN disclosed
CN-106458966-B pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors 诺华股份有限公司 2019-05-07 CN disclosed
CN-105683181-B Novel aminopyrimidine derivatives 诺华股份有限公司 2019-04-23 CN disclosed
CN-106458966-A Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors 诺华股份有限公司 2017-02-22 CN disclosed
CN-106458979-A Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors 诺华股份有限公司 2017-02-22 CN disclosed
CN-106458980-A Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors 诺华股份有限公司 2017-02-22 CN disclosed
CN-104011045-B Dihydrobenzoxazine and dihydropyridinooxazine derivatives 诺华股份有限公司 2016-08-24 CN disclosed
EP-1885352-A2 COMBINATIONS COMPRISING JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS Novartis AG (US) 2008-02-13 EP disclosed
WO-2006056399-A2 COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS NOVARTIS AG (CH) 2006-06-01 WO disclosed